_ Paul Knoepfler (2015). Delivery and Specificity of CRISPR/Cas9 Genome Editing Technologies for _____________ ___ ___ Human Gene Therapy. M., Nijhuis M., Wiertz E. L., Shen, S., Welstead, G. _____ ________ __________ _________ ________ _____________. CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections. S., Fleisher T., Clerici M., Shearer G., Chang L., Chiang Y., Tolstoshev P., Greenblatt J. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years (____.) // Science : journal. Construction and applications of a highly transmissible murine retrovirus shuttle vector (____.) // Cell : journal. J., Muul L., Morgan R. _ UK medicines regulator approves gene therapy for two blood disorders (_____.) _____ _______ ___________ _____, ________ __ ___, _______ __ _____ ____________